greeksoup/ stock research

Utah Medical Products Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 22 October 2026: press release. Guidance figures: 1 raised, 1 new. The quarter’s numbers.

Key takeaways

  • Revenue fell 12% in quarter: Third-quarter revenue was $8,621, down $1,191 (12.1%); nine-month revenue was $25,873, down $3,602 (12.1%). Source
  • Operating income rose in quarter: Third-quarter operating income was $2,795, up 7.0%, with a 32.4% margin against 26.6%. Nine-month operating income was $8,009, down 10.6%. Source
  • Filshie sales fell sharply in quarter: Worldwide Filshie sales fell $805 (32.7%) in the quarter, with domestic Filshie sales $534 lower. Nine-month Filshie sales were $1,194 (15.7%) lower. Source
  • Former top customers produced no sales: Sales to PendoTECH and the former China BPM kit distributor were zero in 2026. Those two were $491 of 3Q 2025 sales and $2,419 of 9M 2025 sales. Source
  • Quarter gross margin fell on lower sales: Third-quarter gross margin was 56.1% against 57.1%. Gross profit was $764 (13.6%) lower on 12.1% lower sales. Source
  • Cash held near year-end level: Cash and investments were $85.2 million at September 30, against $85.8 million at year-end 2025, with no debt. Source

“The lower sales in comparison with the prior year’s periods were substantially a result of a lack of any 2026 sales to UTMD’s two previously largest customers”

Utah Medical Products Inc., press release

Guidance

AreaPeriodFigureAgainst last quarter
Consolidated sales SourceFull year 2026decline close to 7%Raised from sales decline of 10-13% compared to 2025
Replacement sales from former customers SourceFourth quarter 2026higher than both former 4Q periods ($35 in 4Q 2025 and $338 in 4Q 2024)New

What changed from last quarter

  • Guidance raised: The full-year 2026 sales projection moved to a decline close to 7%, from the prior release's projected decline of 10-13%. Source
  • New: Femcare acquired Orion Medical Supplies Ltd in the UK at the end of August 2026; the company reported the acquisition added sales in the third quarter. Source
  • New guidance: Management stated an expectation for combined fourth-quarter 2026 replacement sales to the two former customers, which the prior release did not give. Source

Results and growth drivers

  • Revenue fell 12% in quarter: Third-quarter revenue was $8,621, down $1,191 (12.1%); nine-month revenue was $25,873, down $3,602 (12.1%). Source
  • Operating income rose in quarter: Third-quarter operating income was $2,795, up 7.0%, with a 32.4% margin against 26.6%. Nine-month operating income was $8,009, down 10.6%. Source
  • Diluted EPS up in quarter: Third-quarter diluted EPS was $0.876 against $0.820, up 6.8%. Nine-month diluted EPS was $2.537 against $2.680, down 5.3%. Source
  • Nine-month net income fell: Nine-month net income was $8,077, down 7.4%. Third-quarter net income was $2,787, up 5.9%. Source

Segments and regions

  • Domestic sales fell in quarter: Domestic sales were $4,917 in the quarter, 16.1% lower. Nine-month domestic sales were $15,644, 9.6% lower. Source
  • Outside-U.S. sales flat excluding China: Outside the U.S., nine-month sales were $10,229, down 15.9%. Excluding the former China distributor, net of the new one, they were $75 (0.6%) lower. Source
  • Filshie sales fell sharply in quarter: Worldwide Filshie sales fell $805 (32.7%) in the quarter, with domestic Filshie sales $534 lower. Nine-month Filshie sales were $1,194 (15.7%) lower. Source
  • NICU devices lower over nine months: Domestic NICU device sales were 18% lower over nine months; other domestic categories excluding Filshie were 6-8% lower. Source
  • Currency effects small: Exchange rates reduced third-quarter sales by $14 and added $170 to nine-month sales, each under one percentage point of sales. Source

Products and customers

  • Former top customers produced no sales: Sales to PendoTECH and the former China BPM kit distributor were zero in 2026. Those two were $491 of 3Q 2025 sales and $2,419 of 9M 2025 sales. Source
  • New China distributor placed first order: A new China BPM kit distributor contributed $195 of sales in the quarter, its first sales since the prior distributor was lost a year earlier. Source
  • New biopharma sales slower than expected: New biopharma customers added $116 of third-quarter sales and $327 for nine months, against the growth management had projected. Source

Costs, margins and pricing

  • Quarter gross margin fell on lower sales: Third-quarter gross margin was 56.1% against 57.1%. Gross profit was $764 (13.6%) lower on 12.1% lower sales. Source
  • Nine-month gross margin higher on mix: Nine-month gross margin was 57.5% against 56.8%, helped by the absence of 2025 sales to the China distributor, which carried very low margin. Source
  • Litigation and amortization costs fell: Combined litigation and intangible amortization was $228 in the quarter, against $920 a year earlier. Femcare intangible amortization was completed in the first quarter of 2026. Source
  • Tax provision rate lower: The average tax provision rate was 18.1% in the quarter against 20.5%, and 18.2% for nine months against 20.8%. Source

Demand and the order book

  • Inventory built to hold production: Inventories rose $2,636 since year-end to $10,571. Inventory turns fell to 1.6 as work-in-process and finished goods were increased to keep productivity up. Source
  • Receivable days lengthened: Average age of trade receivables was 41 days at September 30, up from 35 days at December 31, 2025. Receivables rose $439 since year-end. Source
  • Domestic OEM sales higher: Domestic OEM sales were $677 in the quarter, $41 higher, including $66 more from new domestic biopharma customers. Source
  • Current liabilities rose: Current liabilities rose $2,142 since year-end, and the current ratio fell to 21.2 from 37.6. Source

Operating expenses by category

  • G&A down $936 in quarter: Third-quarter G&A was $936 lower than a year earlier, from several differences, including items in the prior-year quarter and lower Femcare amortization. Source
  • Sales and marketing rose slightly: Sales and marketing was $529 in the quarter against $516. Excluding currency effects, the increase came from U.S. trade show costs and higher OUS salaries. Source
  • R&D expense broadly steady: R&D was $142 in the quarter against $167, and $450 for nine months against $457, reflecting project costs and salary changes. Source

Capital, cash and returns to shareholders

  • Cash held near year-end level: Cash and investments were $85.2 million at September 30, against $85.8 million at year-end 2025, with no debt. Source
  • Orion purchase and equipment spending: Orion Medical Supplies was bought for $5.0 million including legal fees and duties. Plant and equipment spending was $0.5 million year to date. Source
  • Dividends paid and shares bought back: Nine-month dividends were $2,963 ($0.310 a share). Share repurchases cost $905 at an average of $67.51 a share. Source
  • Outstanding share count reduced: Outstanding shares fell to 3,175,006 at September 30 from 3,186,221 at year-end 2025, after 13,403 shares were repurchased and 2,188 options exercised. Source

Coming up, as management said on 22 October 2026

  • Quarterly 10-Q with segment detail: The company said further sales explanation and segment detail will appear in its 3Q 2026 Form 10-Q, due in November. Source
  • China distributor may match prior demand: Management said the new China BPM kit distributor might eventually match the demand of the prior distributor. Source

Figures management reported

FigureReported
Worldwide Filshie device sales, 3Q 2026 Source$805 lower (32.7%)
Worldwide NICU device sales, 9M 2026 Source$1,105 lower (17.7%)
New biopharma customer sales, 9M 2026 Source$327
New China BPM kit distributor sales, 3Q 2026 Source$195
Domestic OEM sales, 3Q 2026 Source$677

Risks management discussed

  • Regulatory: Two of the four remaining unresolved U.S. Filshie cases, out of nineteen, are expected to go to trial in 2027; the other two await summary judgment decisions. Source
  • Operational: UTMD Ltd in Ireland makes the Filshie Clip System for all UTMD subsidiaries, so lower intercompany Filshie sales affect Irish output and gross margin. Source
  • Operational: Labor and overhead were kept at prior levels for expected biopharma control device growth while trade shipments were lower. Source
  • Financial: Sales invoiced in foreign currencies were 32% of third-quarter consolidated sales, up from 29%, including Orion for the first time. Source
  • Financial: Non-operating income was $92 lower in the quarter and $183 lower for nine months, due to lower interest rates on cash deposits. Source

Earlier plans management reported on

  • Delayed: Management said sales to other biopharma OEM customers have not developed as soon as projected at the beginning of the year. Source
  • Met: Management said the zero 2026 sales to PendoTECH and the China distributor were consistent with the 10-K projection made at the start of the year. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.